Claudia Amura
Concepts (345)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 3 | 2025 | 634 | 0.970 |
Why?
| | Opiate Substitution Treatment | 2 | 2025 | 195 | 0.780 |
Why?
| | Telemedicine | 4 | 2024 | 966 | 0.730 |
Why?
| | Needs Assessment | 1 | 2024 | 404 | 0.650 |
Why?
| | Buprenorphine | 2 | 2022 | 197 | 0.650 |
Why?
| | Cysts | 4 | 2009 | 108 | 0.610 |
Why?
| | Health Personnel | 1 | 2024 | 754 | 0.500 |
Why?
| | Liver Diseases | 3 | 2009 | 304 | 0.470 |
Why?
| | Reperfusion Injury | 3 | 2013 | 300 | 0.430 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 3 | 2009 | 244 | 0.420 |
Why?
| | Kidney Tubules | 2 | 2012 | 117 | 0.420 |
Why?
| | Macrophage Activation | 3 | 1998 | 182 | 0.380 |
Why?
| | Colorado | 6 | 2025 | 4595 | 0.370 |
Why?
| | Cyst Fluid | 3 | 2009 | 20 | 0.350 |
Why?
| | Complement Factor B | 1 | 2012 | 106 | 0.340 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 125 | 0.340 |
Why?
| | TRPP Cation Channels | 3 | 2009 | 76 | 0.330 |
Why?
| | Cytokines | 7 | 2012 | 2081 | 0.310 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 277 | 0.310 |
Why?
| | Complement Activation | 2 | 2012 | 412 | 0.300 |
Why?
| | Liver | 3 | 2008 | 1864 | 0.290 |
Why?
| | Pandemics | 4 | 2024 | 1707 | 0.280 |
Why?
| | Acute-Phase Proteins | 2 | 1998 | 66 | 0.270 |
Why?
| | HIV Infections | 1 | 2024 | 3215 | 0.270 |
Why?
| | Receptors, Interleukin-8B | 1 | 2008 | 29 | 0.260 |
Why?
| | Lipopolysaccharides | 5 | 1999 | 861 | 0.250 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 109 | 0.250 |
Why?
| | Pyrroles | 2 | 2009 | 222 | 0.250 |
Why?
| | Interleukin-8 | 1 | 2008 | 268 | 0.240 |
Why?
| | Cell Proliferation | 3 | 2009 | 2502 | 0.240 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2005 | 14 | 0.230 |
Why?
| | Epithelial Cells | 5 | 2012 | 1119 | 0.230 |
Why?
| | Membrane Glycoproteins | 2 | 1998 | 495 | 0.220 |
Why?
| | Neurofilament Proteins | 1 | 2005 | 83 | 0.220 |
Why?
| | Pluripotent Stem Cells | 1 | 2005 | 78 | 0.220 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 866 | 0.210 |
Why?
| | Indoles | 2 | 2009 | 511 | 0.200 |
Why?
| | Piroxicam | 5 | 1995 | 5 | 0.200 |
Why?
| | Program Development | 1 | 2025 | 371 | 0.200 |
Why?
| | Interleukin-1 | 3 | 1995 | 960 | 0.180 |
Why?
| | Membrane Proteins | 3 | 2010 | 1130 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 1998 | 1224 | 0.180 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6073 | 0.180 |
Why?
| | Labor Pain | 1 | 2022 | 12 | 0.180 |
Why?
| | Midwifery | 1 | 2023 | 70 | 0.180 |
Why?
| | Nitrous Oxide | 1 | 2022 | 34 | 0.170 |
Why?
| | Analgesia, Obstetrical | 1 | 2022 | 33 | 0.170 |
Why?
| | Interviews as Topic | 1 | 2025 | 930 | 0.170 |
Why?
| | Mice | 19 | 2013 | 18297 | 0.170 |
Why?
| | Cells, Cultured | 6 | 2012 | 4118 | 0.170 |
Why?
| | Health Services Needs and Demand | 1 | 2024 | 287 | 0.170 |
Why?
| | Program Evaluation | 1 | 2025 | 952 | 0.170 |
Why?
| | Chemotaxis, Leukocyte | 4 | 1995 | 115 | 0.170 |
Why?
| | Macrophages, Peritoneal | 2 | 1998 | 89 | 0.160 |
Why?
| | Pseudomonas aeruginosa | 5 | 1995 | 392 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2025 | 317 | 0.160 |
Why?
| | Academic Performance | 1 | 2021 | 16 | 0.160 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2005 | 902 | 0.160 |
Why?
| | Faculty, Nursing | 1 | 2021 | 31 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 1 | 2007 | 983 | 0.160 |
Why?
| | Rural Population | 1 | 2025 | 677 | 0.160 |
Why?
| | Patient-Centered Care | 1 | 2025 | 553 | 0.160 |
Why?
| | Education, Nursing, Graduate | 1 | 2021 | 37 | 0.160 |
Why?
| | Mice, Knockout | 5 | 2012 | 3125 | 0.150 |
Why?
| | Intimate Partner Violence | 1 | 2022 | 93 | 0.150 |
Why?
| | Crime Victims | 1 | 2022 | 131 | 0.150 |
Why?
| | Asthma | 2 | 2023 | 1800 | 0.150 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1107 | 0.150 |
Why?
| | Students, Nursing | 1 | 2021 | 94 | 0.140 |
Why?
| | Chemotactic Factors | 3 | 1993 | 43 | 0.140 |
Why?
| | Pilot Projects | 2 | 2022 | 1888 | 0.140 |
Why?
| | Humans | 22 | 2025 | 146342 | 0.140 |
Why?
| | Agranulocytosis | 2 | 1995 | 30 | 0.140 |
Why?
| | Kidney | 3 | 2013 | 1498 | 0.140 |
Why?
| | Lung Diseases | 2 | 1995 | 787 | 0.130 |
Why?
| | Perception | 1 | 2021 | 373 | 0.130 |
Why?
| | Animals | 26 | 2013 | 38106 | 0.130 |
Why?
| | Altitude | 1 | 2022 | 469 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 881 | 0.130 |
Why?
| | Carrier Proteins | 2 | 1998 | 728 | 0.130 |
Why?
| | Mice, Inbred C57BL | 6 | 2012 | 6034 | 0.130 |
Why?
| | Anti-Asthmatic Agents | 1 | 2019 | 263 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2024 | 947 | 0.120 |
Why?
| | Female | 19 | 2025 | 79499 | 0.120 |
Why?
| | Neurons | 1 | 2005 | 1668 | 0.120 |
Why?
| | Pseudomonas Infections | 2 | 1995 | 229 | 0.120 |
Why?
| | Neutrophils | 4 | 1995 | 1133 | 0.110 |
Why?
| | Sepsis | 2 | 1999 | 669 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2019 | 536 | 0.110 |
Why?
| | Mice, Inbred C3H | 4 | 1998 | 252 | 0.110 |
Why?
| | Signal Transduction | 4 | 2012 | 5246 | 0.100 |
Why?
| | Promoter Regions, Genetic | 3 | 2008 | 1242 | 0.100 |
Why?
| | Length of Stay | 1 | 2019 | 1358 | 0.100 |
Why?
| | Adult | 4 | 2025 | 41087 | 0.090 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1221 | 0.090 |
Why?
| | Male | 11 | 2025 | 73396 | 0.090 |
Why?
| | Endothelial Cells | 2 | 2009 | 876 | 0.090 |
Why?
| | Immunity, Humoral | 1 | 2013 | 121 | 0.090 |
Why?
| | Copper | 1 | 1993 | 122 | 0.090 |
Why?
| | Health Behavior | 1 | 2018 | 802 | 0.090 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 416 | 0.090 |
Why?
| | Cell Line | 2 | 2008 | 2814 | 0.080 |
Why?
| | Emergency Service, Hospital | 2 | 2023 | 2363 | 0.080 |
Why?
| | Superoxide Dismutase | 1 | 1993 | 307 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2009 | 87 | 0.080 |
Why?
| | Complement Inactivator Proteins | 1 | 2010 | 39 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2018 | 635 | 0.080 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 78 | 0.080 |
Why?
| | Receptors, Complement | 1 | 2010 | 126 | 0.080 |
Why?
| | Graft Rejection | 1 | 2013 | 516 | 0.070 |
Why?
| | Complement Factor H | 1 | 2010 | 81 | 0.070 |
Why?
| | United States | 2 | 2025 | 16136 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2013 | 428 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2007 | 2022 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2009 | 545 | 0.070 |
Why?
| | Chemokine CXCL5 | 1 | 2008 | 20 | 0.070 |
Why?
| | Cell Shape | 1 | 2008 | 56 | 0.070 |
Why?
| | Chemokine CXCL1 | 1 | 2008 | 76 | 0.070 |
Why?
| | Antimicrobial Cationic Peptides | 2 | 1998 | 81 | 0.070 |
Why?
| | Blood Proteins | 3 | 1998 | 239 | 0.060 |
Why?
| | Injections, Intraperitoneal | 3 | 1998 | 115 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2008 | 1432 | 0.060 |
Why?
| | Aged | 2 | 2025 | 26432 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2005 | 1982 | 0.060 |
Why?
| | Cell Polarity | 1 | 2008 | 138 | 0.060 |
Why?
| | Cell Hypoxia | 1 | 2008 | 249 | 0.060 |
Why?
| | Epithelial Sodium Channels | 1 | 2006 | 22 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2007 | 74 | 0.060 |
Why?
| | Bile Ducts | 1 | 2006 | 66 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 735 | 0.060 |
Why?
| | Mice, Neurologic Mutants | 1 | 2005 | 21 | 0.060 |
Why?
| | Wnt4 Protein | 1 | 2005 | 19 | 0.060 |
Why?
| | Exercise | 1 | 2018 | 2213 | 0.060 |
Why?
| | Stress, Mechanical | 1 | 2008 | 497 | 0.060 |
Why?
| | Luciferases | 1 | 2005 | 153 | 0.060 |
Why?
| | Transfection | 1 | 2008 | 916 | 0.060 |
Why?
| | Middle Aged | 2 | 2025 | 36619 | 0.060 |
Why?
| | Genes, Reporter | 1 | 2005 | 275 | 0.050 |
Why?
| | Embryo, Mammalian | 1 | 2005 | 230 | 0.050 |
Why?
| | Wnt Proteins | 1 | 2005 | 131 | 0.050 |
Why?
| | Disease Models, Animal | 4 | 2009 | 4580 | 0.050 |
Why?
| | Nerve Growth Factor | 1 | 2004 | 36 | 0.050 |
Why?
| | Electronic Health Records | 2 | 2025 | 1210 | 0.050 |
Why?
| | Cadherins | 1 | 2005 | 202 | 0.050 |
Why?
| | Peroxidase | 2 | 1995 | 168 | 0.050 |
Why?
| | Down-Regulation | 1 | 2005 | 614 | 0.050 |
Why?
| | Time Factors | 4 | 2007 | 7109 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 752 | 0.050 |
Why?
| | Proto-Oncogene Proteins | 1 | 2005 | 616 | 0.040 |
Why?
| | Certification | 1 | 2023 | 118 | 0.040 |
Why?
| | Tennessee | 1 | 2022 | 57 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2023 | 186 | 0.040 |
Why?
| | North Carolina | 1 | 2022 | 127 | 0.040 |
Why?
| | Nurse's Role | 1 | 2023 | 148 | 0.040 |
Why?
| | Workflow | 1 | 2023 | 182 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2005 | 2791 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2006 | 776 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2008 | 2240 | 0.040 |
Why?
| | House Calls | 1 | 2022 | 154 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 3545 | 0.040 |
Why?
| | Pregnancy | 2 | 2023 | 7230 | 0.040 |
Why?
| | Policy | 1 | 2020 | 147 | 0.040 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 1999 | 55 | 0.040 |
Why?
| | Thioglycolates | 1 | 1998 | 3 | 0.040 |
Why?
| | Galactosamine | 1 | 1998 | 3 | 0.040 |
Why?
| | Immune Sera | 1 | 1998 | 77 | 0.040 |
Why?
| | Monoamine Oxidase | 2 | 1975 | 27 | 0.030 |
Why?
| | Violence | 1 | 2022 | 275 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2025 | 733 | 0.030 |
Why?
| | Kinetics | 3 | 1998 | 1553 | 0.030 |
Why?
| | Blood Bactericidal Activity | 1 | 1997 | 38 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 1998 | 1361 | 0.030 |
Why?
| | Interleukin-12 | 1 | 1998 | 115 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 790 | 0.030 |
Why?
| | Adrenalectomy | 2 | 1975 | 68 | 0.030 |
Why?
| | Microsomes, Liver | 2 | 1979 | 85 | 0.030 |
Why?
| | Biological Transport | 1 | 1998 | 424 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2019 | 257 | 0.030 |
Why?
| | Enzyme Activation | 1 | 1998 | 759 | 0.030 |
Why?
| | Immunization | 1 | 1998 | 376 | 0.030 |
Why?
| | Leadership | 1 | 2021 | 414 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 497 | 0.030 |
Why?
| | Interleukin-10 | 1 | 1998 | 310 | 0.030 |
Why?
| | Trypanosoma | 1 | 1975 | 8 | 0.030 |
Why?
| | Rats | 5 | 2004 | 5586 | 0.030 |
Why?
| | Child | 3 | 2023 | 22693 | 0.030 |
Why?
| | In Vitro Techniques | 3 | 1993 | 1041 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 561 | 0.030 |
Why?
| | Benzylamine Oxidase | 1 | 1975 | 1 | 0.030 |
Why?
| | Child Behavior | 1 | 2018 | 234 | 0.030 |
Why?
| | Mothers | 1 | 2022 | 772 | 0.030 |
Why?
| | Qualitative Research | 1 | 2023 | 1734 | 0.030 |
Why?
| | Acute-Phase Reaction | 1 | 1995 | 37 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2004 | 2599 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 429 | 0.030 |
Why?
| | ADP Ribose Transferases | 1 | 1995 | 9 | 0.030 |
Why?
| | Exotoxins | 1 | 1995 | 16 | 0.030 |
Why?
| | Parent-Child Relations | 1 | 2018 | 266 | 0.030 |
Why?
| | Monocytes | 1 | 1997 | 538 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1975 | 84 | 0.030 |
Why?
| | Mutation | 1 | 2005 | 4093 | 0.030 |
Why?
| | Bacterial Toxins | 1 | 1995 | 110 | 0.030 |
Why?
| | Superoxides | 1 | 1995 | 198 | 0.030 |
Why?
| | Quality Improvement | 1 | 2023 | 1354 | 0.020 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1993 | 82 | 0.020 |
Why?
| | Copper Sulfate | 1 | 1993 | 8 | 0.020 |
Why?
| | Aggression | 1 | 1975 | 171 | 0.020 |
Why?
| | Virulence Factors | 1 | 1995 | 175 | 0.020 |
Why?
| | Cytochrome c Group | 1 | 1993 | 43 | 0.020 |
Why?
| | Edetic Acid | 1 | 1993 | 47 | 0.020 |
Why?
| | Antibody Formation | 2 | 2010 | 290 | 0.020 |
Why?
| | Registries | 1 | 2022 | 2400 | 0.020 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 1992 | 61 | 0.020 |
Why?
| | Lung | 3 | 1995 | 4122 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2022 | 17438 | 0.020 |
Why?
| | Edema | 1 | 1993 | 131 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1849 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 1993 | 567 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2921 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 120 | 0.020 |
Why?
| | Receptors, Complement 3b | 1 | 2010 | 83 | 0.020 |
Why?
| | Transcription Factors | 1 | 1998 | 1730 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1408 | 0.020 |
Why?
| | Macrophages | 1 | 1998 | 1532 | 0.020 |
Why?
| | Peptidylprolyl Isomerase | 1 | 2009 | 9 | 0.020 |
Why?
| | NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2009 | 22 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 1992 | 344 | 0.020 |
Why?
| | Complement Pathway, Alternative | 1 | 2010 | 123 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 1993 | 1075 | 0.020 |
Why?
| | Adolescent | 2 | 2019 | 22557 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2458 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2010 | 284 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 404 | 0.020 |
Why?
| | Birds | 1 | 1979 | 87 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2004 | 1031 | 0.020 |
Why?
| | Pneumonia | 1 | 1994 | 635 | 0.020 |
Why?
| | Aniline Compounds | 1 | 1979 | 120 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 846 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1177 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 287 | 0.020 |
Why?
| | Receptors, Purinergic P2X4 | 1 | 2006 | 6 | 0.020 |
Why?
| | Amiloride | 1 | 2006 | 25 | 0.020 |
Why?
| | Receptors, Purinergic P2 | 1 | 2006 | 23 | 0.020 |
Why?
| | Ion Transport | 1 | 2006 | 61 | 0.020 |
Why?
| | Chlorine | 1 | 2006 | 59 | 0.020 |
Why?
| | Protein Binding | 2 | 2010 | 2244 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1712 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2006 | 384 | 0.010 |
Why?
| | Pentanones | 1 | 1975 | 3 | 0.010 |
Why?
| | Cyclic AMP | 1 | 2006 | 208 | 0.010 |
Why?
| | Digitoxin | 1 | 1975 | 5 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 823 | 0.010 |
Why?
| | Sodium | 1 | 2006 | 196 | 0.010 |
Why?
| | Enzyme Induction | 1 | 1975 | 87 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 1992 | 980 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 1992 | 927 | 0.010 |
Why?
| | Ketones | 1 | 1975 | 51 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 3 | 1979 | 533 | 0.010 |
Why?
| | Synapsins | 1 | 2004 | 13 | 0.010 |
Why?
| | PC12 Cells | 1 | 2004 | 42 | 0.010 |
Why?
| | Phosphorylation | 1 | 2009 | 1724 | 0.010 |
Why?
| | Young Adult | 1 | 2022 | 14330 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 153 | 0.010 |
Why?
| | Arginine | 1 | 1975 | 264 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2006 | 494 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2004 | 193 | 0.010 |
Why?
| | Antipsychotic Agents | 1 | 1976 | 185 | 0.010 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 174 | 0.010 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2004 | 250 | 0.010 |
Why?
| | Lysine | 1 | 1975 | 303 | 0.010 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 2 | 1993 | 38 | 0.010 |
Why?
| | Piperazines | 1 | 1975 | 368 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2004 | 369 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2009 | 952 | 0.010 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2004 | 320 | 0.010 |
Why?
| | Brain | 1 | 1975 | 2991 | 0.010 |
Why?
| | Schizophrenia | 1 | 1976 | 537 | 0.010 |
Why?
| | Proteins | 1 | 1975 | 1022 | 0.010 |
Why?
| | Antiviral Agents | 1 | 1975 | 779 | 0.010 |
Why?
| | Spermine | 1 | 1999 | 29 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1992 | 2675 | 0.010 |
Why?
| | Gram-Negative Bacteria | 1 | 1999 | 80 | 0.010 |
Why?
| | Neutralization Tests | 1 | 1998 | 74 | 0.010 |
Why?
| | Glycine | 1 | 1999 | 184 | 0.010 |
Why?
| | Hydroxylation | 2 | 1979 | 47 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1792 | 0.010 |
Why?
| | DNA Primers | 1 | 1998 | 487 | 0.010 |
Why?
| | Liver Glycogen | 1 | 1975 | 16 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1975 | 69 | 0.010 |
Why?
| | Ammonium Sulfate | 1 | 1975 | 8 | 0.010 |
Why?
| | Dopa Decarboxylase | 1 | 1975 | 1 | 0.010 |
Why?
| | Pimozide | 1 | 1975 | 3 | 0.010 |
Why?
| | Tubocurarine | 1 | 1975 | 6 | 0.010 |
Why?
| | Hydroxydopamines | 1 | 1975 | 4 | 0.010 |
Why?
| | Apomorphine | 1 | 1975 | 6 | 0.010 |
Why?
| | Carbachol | 1 | 1975 | 17 | 0.010 |
Why?
| | Dopamine beta-Hydroxylase | 1 | 1975 | 13 | 0.010 |
Why?
| | Acetylcholinesterase | 1 | 1975 | 10 | 0.010 |
Why?
| | Dihydroxyphenylalanine | 1 | 1975 | 11 | 0.010 |
Why?
| | Parasympatholytics | 1 | 1975 | 11 | 0.010 |
Why?
| | Amantadine | 1 | 1975 | 8 | 0.010 |
Why?
| | Choline O-Acetyltransferase | 1 | 1975 | 26 | 0.010 |
Why?
| | Monoamine Oxidase Inhibitors | 1 | 1975 | 20 | 0.010 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1975 | 24 | 0.010 |
Why?
| | Cholinesterase Inhibitors | 1 | 1975 | 47 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1998 | 781 | 0.010 |
Why?
| | Base Sequence | 1 | 1998 | 2123 | 0.010 |
Why?
| | Dogs | 1 | 1975 | 517 | 0.010 |
Why?
| | Nitric Oxide | 1 | 1998 | 883 | 0.010 |
Why?
| | Culture Media | 1 | 1993 | 161 | 0.010 |
Why?
| | Aerosols | 1 | 1993 | 146 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1992 | 238 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 1998 | 1512 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1993 | 642 | 0.010 |
Why?
| | Glucose | 1 | 1975 | 1053 | 0.000 |
Why?
| | Mice, Inbred BALB C | 1 | 1992 | 1244 | 0.000 |
Why?
| | Dealkylation | 1 | 1979 | 3 | 0.000 |
Why?
| | Oxidoreductases, N-Demethylating | 1 | 1979 | 17 | 0.000 |
Why?
| | Inactivation, Metabolic | 1 | 1979 | 9 | 0.000 |
Why?
| | Phenotype | 1 | 1998 | 3206 | 0.000 |
Why?
| | Combined Modality Therapy | 1 | 1992 | 1271 | 0.000 |
Why?
| | Species Specificity | 1 | 1979 | 543 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1979 | 563 | 0.000 |
Why?
| | Promazine | 1 | 1976 | 1 | 0.000 |
Why?
| | Trifluoperazine | 1 | 1976 | 3 | 0.000 |
Why?
| | Chlorpromazine | 1 | 1976 | 5 | 0.000 |
Why?
| | Basal Ganglia Diseases | 1 | 1976 | 10 | 0.000 |
Why?
| | Micrococcus | 1 | 1975 | 4 | 0.000 |
Why?
| | Digitoxigenin | 1 | 1975 | 3 | 0.000 |
Why?
| | Tyrosine Transaminase | 1 | 1975 | 4 | 0.000 |
Why?
| | Chromatography, Thin Layer | 1 | 1975 | 24 | 0.000 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 1975 | 82 | 0.000 |
Why?
| | Cortisone | 1 | 1975 | 16 | 0.000 |
Why?
| | Culture Techniques | 1 | 1975 | 65 | 0.000 |
Why?
| | NADP | 1 | 1975 | 52 | 0.000 |
Why?
| | Muramidase | 1 | 1975 | 66 | 0.000 |
Why?
| | Tryptophan Oxygenase | 1 | 1975 | 33 | 0.000 |
Why?
| | Movement Disorders | 1 | 1976 | 68 | 0.000 |
Why?
| | Tyrosine | 1 | 1975 | 217 | 0.000 |
Why?
| | Imidazoles | 1 | 1975 | 245 | 0.000 |
Why?
| | Protein Conformation | 1 | 1975 | 916 | 0.000 |
Why?
| | Recurrence | 1 | 1976 | 1133 | 0.000 |
Why?
| | Binding Sites | 1 | 1975 | 1309 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1976 | 1064 | 0.000 |
Why?
| | Chronic Disease | 1 | 1976 | 1827 | 0.000 |
Why?
|
|
Amura's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|